Sfoglia per AUTORE
POTHURI B
Collezione AO Ordine Mauriziano

  

Items : 6

Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial. in International journal of gynecological cancer : official journal of the International Gynecological Cancer Society / Int J Gynecol Cancer. 2024 Sep 25:ijgc-2024-005484. doi: 10.1136/ijgc-2024-005484.
2024
AO Ordine Mauriziano

Mirza MR; Black D; Garside J; Meyers O; Vincent V; Chase D; Secord AA; Valabrega G; Powell MA; Pothuri B; Stuckey A; Sharma S; Herzog TJ; Monk BJ; Cloven N; Podzielinski I; Gogoi R; Ataseven B; Landrum LM; Zub O; Fleming E; Gilbert L; Thijs AM; Pennington KP; Myers T; Denschlag D; Holloway R; Novak Z; Miller EM; et alii...

A Plain Language Summary of "Dostarlimab for primary advanced or recurrent endometrial cancer". in Future oncology (London, England) / Future Oncol. 2024 Jul 11:1-18. doi: 10.2217/fon-2023-0940.
2024
AO Ordine Mauriziano

Powell MA; Coleman RL; Gilbert L; Sharma S; Valabrega G; Landrum LM; Hanker LC; Stuckey A; Boere I; Stevens S; Zografos E; Tian M; He Z; Copeland LJ; Herzog TJ; Buscema J; Monk BJ; Gill SE; Shahin MS; Raspagliesi F; McCourt C; Pothuri B; Cibula D; Auranen A; Gold MA; Black D; Novák Z; Christensen RD; Slomovitz BM; et alii...

Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2024 Aug;35(8):728-738. doi: 10.1016/j.annonc.2024.05.546. Epub 2024 Jun 10.
2024
AO Ordine Mauriziano

McCourt C; Mirza MR; Stevens S; Grimshaw M; Balas MM; Ring KL; Herzog TJ; Slomovitz BM; Buscema J; Coleman RL; Monk BJ; Pothuri B; Sebastianelli A; Shahin MS; Gennigens C; Segev Y; Gill SE; Gold MA; Boere I; Stuckey A; Lai DW; Gropp-Meier M; Landrum LM; Valabrega G; Sharma S; Gilbert L; Black D; Novák Z; Willmott L; et alii...

Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial. in Gynecologic oncology / Gynecol Oncol. 2024 Aug;187:128-138. doi: 10.1016/j.ygyno.2024.03.009. Epub 2024 Jun 3.
2024
AO Ordine Mauriziano

Sánchez AB; McCormick C; Baurain JF; González-Martín A; York W; Gupta D; Monk BJ; Valabrega G; Pothuri B; Levy T; Heitz F; Knudsen AØ; de La Motte Rouge T; Moore RG; Hietanen S; O'Cearbhaill RE; Tinker AV; Denys H; Graybill WS; Oaknin A;

Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2023 Sep 5:JCO2202906. doi: 10.1200/JCO.22.02906.
2023
AO Ordine Mauriziano

Vergote I; Pérez-Fidalgo JA; Hamilton EP; Valabrega G; Gorp TV; Sehouli J; Cibula D; Levy T; Welch S; Richardson DL; Guerra EM; Scambia G; Henry S; Wimberger P; Miller DS; Klat J; Martínez-Garcia J; Raspagliesi F; Pothuri B; Romero I; Bergamini A; Slomovitz B; Schochter F; Høgdall E; Fariñas-Madrid L; Monk BJ; Michel D; Kauffman MG; Shacham S; et alii...

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. in The New England journal of medicine / N Engl J Med. 2023 Jun 8;388(23):2145-2158. doi: 10.1056/NEJMoa2216334. Epub 2023 Mar 27.
2023
AO Ordine Mauriziano

Powell MA; Coleman RL; Zografos E; Stevens S; He Z; Tian M; Copeland LJ; Herzog TJ; Buscema J; Monk BJ; Gill SE; Shahin MS; Raspagliesi F; McCourt C; Cibula D; Pothuri B; Auranen A; Gold MA; Boere I; Stuckey A; Hanker LC; Landrum LM; Valabrega G; Sharma S; Gilbert L; Black D; dePont Christensen R; Novák Z; Slomovitz BM; et alii...